Large, brand-name drugmakers could lose $1 trillion in sales and remain profitable enough to maintain their current investments in research and development, according to a report released last week by West Health and Johns Hopkins Bloomberg School of Public Health. Sean Dickson, director of health policy at the West Health Policy Center and the lead author of the analysis, said the findings suggest drug pricing regulations would not substantially harm the industry. (Source: Healthcare Finance News, 11/14)
